Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVEXO
- Development stage
- Preclinical
- Lead developer
- KWHC
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
AVEXO is an acellular secretome therapy being developed by KWHC (KWEHEALTH) for the treatment of musculoskeletal disorders. The therapy is designed to deliver a complex mixture of cell-secreted factors, including growth factors, cytokines, and extracellular vesicles (EVs), derived from therapeutic cells. This secretome-based approach aims to promote tissue repair and regeneration by modulating the local microenvironment and stimulating endogenous healing processes. As an acellular therapy, AVEXO offers potential advantages over traditional cell therapies, such as reduced immunogenicity and simplified storage and handling. It is currently in the preclinical stage of development.
Beyond the preview
Go deeper on AVEXO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVEXO.